{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:06:44Z","timestamp":1793164004173,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bayer US"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40487-025-00377-9","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T07:00:04Z","timestamp":1759906804000},"page":"963-976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1007","volume":"13","author":[{"given":"Samuel","family":"Mehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Hauke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"2","key":"377_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2025","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et\u00a0al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Eur Urol. 2025;86(2):148\u201363.","journal-title":"Eur Urol"},{"issue":"11","key":"377_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180\u201392.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"377_CR3","first-page":"1365","volume":"32","author":"KL Wallace","year":"2021","unstructured":"Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365\u201374.","journal-title":"Cancer Causes Control"},{"issue":"2","key":"377_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227552","volume":"15","author":"J Meht\u00e4l\u00e4","year":"2020","unstructured":"Meht\u00e4l\u00e4 J, Zong J, Vassilev Z, et\u00a0al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS ONE. 2020;15(2):e0227552.","journal-title":"PLoS ONE"},{"issue":"14","key":"377_CR5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly WK, Ma H, et\u00a0al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"377_CR6","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.clinthera.2016.06.018","volume":"38","author":"A Yaldo","year":"2016","unstructured":"Yaldo A, Wen L, Ogbonnaya A, et\u00a0al. Opioid use among metastatic prostate cancer patients with skeletal-related events. Clin Ther. 2016;38(8):1880\u20139.","journal-title":"Clin Ther"},{"issue":"9","key":"377_CR7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et\u00a0al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334.","journal-title":"Ann Oncol"},{"issue":"9","key":"377_CR8","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1093\/oncolo\/oyad046","volume":"28","author":"PC Barata","year":"2023","unstructured":"Barata PC, Leith A, Ribbands A, et\u00a0al. Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer: results from an international study. Oncologist. 2023;28(9):e737\u201347.","journal-title":"Oncologist"},{"issue":"1","key":"377_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34\u201345.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"377_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, et\u00a0al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"key":"377_CR11","unstructured":"Novartis Pharmaceuticals. PLUVICTO highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf. Accessed July 15, 2025."},{"issue":"13","key":"377_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et\u00a0al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"5","key":"377_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, et\u00a0al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"21","key":"377_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et\u00a0al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"2","key":"377_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, et\u00a0al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"key":"377_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100761","volume":"56","author":"SAJ Buck","year":"2021","unstructured":"Buck SAJ, Koolen SLW, Mathijssen RHJ, de Wit R, van Soest RJ. Cross-resistance and drug sequence in prostate cancer. Drug Resist Updat. 2021;56:100761.","journal-title":"Drug Resist Updat"},{"issue":"22","key":"377_CR17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, et\u00a0al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"8","key":"377_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, et\u00a0al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"377_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242\u20135.","journal-title":"J Clin Oncol"},{"issue":"15","key":"377_CR20","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain A, et\u00a0al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513\u201320.","journal-title":"N Engl J Med"},{"issue":"9747","key":"377_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, et\u00a0al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147\u201354.","journal-title":"Lancet"},{"issue":"6","key":"377_CR22","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/annonc\/mdv129","volume":"26","author":"SE Al-Batran","year":"2015","unstructured":"Al-Batran SE, Hozaeel W, Tauchert FK, et\u00a0al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol. 2015;26(6):1244\u20138.","journal-title":"Ann Oncol"},{"issue":"5","key":"377_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et\u00a0al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"6349","key":"377_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et\u00a0al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science"},{"key":"377_CR25","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Xofigo (radium-223) highlights of prescribing information. https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Xofigo_PI.pdf. Accessed July 2025."},{"issue":"3","key":"377_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","volume":"33","author":"YS Kim","year":"2012","unstructured":"Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 2012;33(3):573\u201390.","journal-title":"Tumour Biol"},{"issue":"3","key":"377_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et\u00a0al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"key":"377_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.10.020","volume":"71","author":"C Parker","year":"2017","unstructured":"Parker C, Zhan L, Cislo P, et\u00a0al. Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised alpharadin in symptomatic prostate cancer patients (ALSYMPCA) trial. Eur J Cancer. 2017;71:1\u20136.","journal-title":"Eur J Cancer"},{"issue":"3","key":"377_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.21037\/tau.2018.02.07","volume":"7","author":"O Sartor","year":"2018","unstructured":"Sartor O, Sharma D. Radium and other alpha emitters in prostate cancer. Transl Androl Urol. 2018;7(3):436\u201344.","journal-title":"Transl Androl Urol"},{"issue":"12","key":"377_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et\u00a0al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10459","key":"377_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, et\u00a0al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"7","key":"377_CR32","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","volume":"26","author":"K Fizazi","year":"2025","unstructured":"Fizazi K, Morris MJ, Shore ND, et\u00a0al. Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial. Lancet Oncol. 2025;26(7):948\u201359.","journal-title":"Lancet Oncol"},{"key":"377_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102524","volume":"115","author":"J Calais","year":"2023","unstructured":"Calais J, Eulau SM, Gardner L, et\u00a0al. Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treat Rev. 2023;115:102524.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"377_CR34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s00259-019-4261-y","volume":"46","author":"S Dizdarevic","year":"2019","unstructured":"Dizdarevic S, Petersen PM, Essler M, et\u00a0al. Interim analysis of the REASSURE (radium-223 alpha emitter agent in non-intervention safety study in mCRPC population for long-term evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. Eur J Nucl Med Mol Imaging. 2019;46(5):1102\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"377_CR35","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"P Hoskin","year":"2014","unstructured":"Hoskin P, Sartor O, O\u2019Sullivan JM, et\u00a0al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397\u2013406.","journal-title":"Lancet Oncol"},{"key":"377_CR36","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"S Gillessen","year":"2024","unstructured":"Gillessen S, Choudhury A, Saad F, et\u00a0al. LBA1 a randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3. Ann Oncol. 2024;35:S1254.","journal-title":"Ann Oncol"},{"issue":"5","key":"377_CR37","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","volume":"49","author":"S Satapathy","year":"2022","unstructured":"Satapathy S, Mittal BR, Sood A, et\u00a0al. 177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging. 2022;49(5):1754\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"33","key":"377_CR38","doi-asserted-by":"publisher","first-page":"55567","DOI":"10.18632\/oncotarget.15698","volume":"8","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Zimbelmann S, Yordanova A, et\u00a0al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget. 2017;8(33):55567\u201374.","journal-title":"Oncotarget"},{"issue":"3","key":"377_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.121.262240","volume":"63","author":"O Sartor","year":"2022","unstructured":"Sartor O, Foug\u00e8re C, Essler M, et\u00a0al. 177Lu-prostate-specific membrane antigen ligand after 223Ra treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience. J Nucl Med. 2022;63(3):410\u20134.","journal-title":"J Nucl Med"},{"issue":"3","key":"377_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030557","volume":"14","author":"J Baumgarten","year":"2022","unstructured":"Baumgarten J, Groener D, Nguyen Ngoc C, et\u00a0al. Safety and efficacy of 177lutetium-PSMA-617 radioligand therapy shortly after failing 223radium-dichloride. Cancers (Basel). 2022;14(3):557.","journal-title":"Cancers (Basel)"},{"issue":"Suppl. 6","key":"377_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1200\/JCO.2023.41.6_suppl.73","volume":"41","author":"K Rahbar","year":"2023","unstructured":"Rahbar K, Essler M, Eiber M, et\u00a0al. Time interval between radium 223 (223Ra) therapy and lutetium-177\u2013prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study. J Clin Oncol. 2023;41(Suppl. 6):73.","journal-title":"J Clin Oncol"},{"key":"377_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.831429","volume":"12","author":"I Tsechelidis","year":"2022","unstructured":"Tsechelidis I, Vrachimis A. PSMA PET in imaging prostate cancer. Front Oncol. 2022;12:831429.","journal-title":"Front Oncol"},{"issue":"1","key":"377_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"F de Galiza Barbosa","year":"2020","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF, et\u00a0al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20(1):23.","journal-title":"Cancer Imaging"},{"issue":"4","key":"377_CR44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.urology.2014.11.031","volume":"85","author":"ND Shore","year":"2015","unstructured":"Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist\u2019s perspective. Urology. 2015;85(4):717\u201324.","journal-title":"Urology"},{"issue":"13","key":"377_CR45","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1007\/s00259-018-4051-y","volume":"45","author":"A Castello","year":"2018","unstructured":"Castello A, Macapinlac HA, Lopci E, Santos EB. Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(13):2256\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"377_CR46","doi-asserted-by":"publisher","first-page":"S323","DOI":"10.1200\/JCO.2019.37.7_suppl.323","volume":"37","author":"R Louhanepessy","year":"2019","unstructured":"Louhanepessy R, Badrising S, van der Noort V, et\u00a0al. Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223). J Clin Oncol. 2019;37:S323.","journal-title":"J Clin Oncol"},{"issue":"4","key":"377_CR47","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/S0090-4295(96)00557-2","volume":"49","author":"HG van der Poel","year":"1997","unstructured":"van der Poel HG, Oosterhof GO, Schaafsma HE, Debruyne FM, Schalken JA. Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology. 1997;49(4):652\u20137.","journal-title":"Urology"},{"key":"377_CR48","doi-asserted-by":"publisher","first-page":"S616","DOI":"10.1016\/j.annonc.2022.07.1504","volume":"33","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Sartor O, Saad F, et\u00a0al. Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial. Ann Oncol. 2022;33:S616\u201352.","journal-title":"Ann Oncol"},{"issue":"2","key":"377_CR49","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","volume":"65","author":"C Pezaro","year":"2014","unstructured":"Pezaro C, Omlin A, Lorente D, et\u00a0al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65(2):270\u20133.","journal-title":"Eur Urol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00377-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:03:16Z","timestamp":1764090196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00377-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00377-9","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samuel Mehrreports payments for professional\u00a0services from Cellectar Biosciences, Novartis, Bayer, Blue Earth Therapeutics, RayzeBio, Perspective Therapeutics, Spectrum Pharmaceuticals and Siemens Healthineers. Ralph Hauke reports payment for expert testimony from TeleDoc; leadership or fiduciary roles with ASCO, Midwest Private Practice Associates ACO, and the Nebraska Oncology Society; and having served on advisory committees to AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}